Ryan Khouri, CTT Pharmaceutical Holdings CEO, buys $335 in CTTH stock

Ryan Khouri, CEO and a director of CTT Pharmaceutical Holdings, Inc. (OTC Markets:CTTH), recently acquired shares in the company. On October 26, 2026, Mr. Khouri purchased 5,880 shares of CTTH common stock at a price of $0.057 per share. The total value of this acquisition amounted to $335.

Following this transaction, Mr. Khouri directly holds 9,442,536 shares of CTT Pharmaceutical Holdings, Inc. The insider purchase comes as the pharmaceutical company, with a market cap of $3.38 million, faces financial headwinds. According to InvestingPro data, CTTH is not profitable over the last twelve months and carries a current ratio of just 0.2, indicating short-term liquidity concerns. The stock has declined roughly 28% over the past six months, though InvestingPro analysis suggests the company may be overvalued at current levels. For investors seeking deeper insights, InvestingPro offers additional tips and comprehensive financial metrics to evaluate CTTH’s investment potential.